Cholestasis

Liver Diseases

Omegaven™ will be initiated at 0.5 gm fat/kg of body weight per day (5cc/kg per day of Omegaven™) for 2 days. On day 3, the rate of Omegaven™ will be increased to 1g/kg (10cc/kg) per day and will remain at this level thereafter unless otherwise indicated.

Omegaven

SSM Health Cardinal Glennon Children's Hospital

Omegaven for Compassionate Use in the Treatment of Parenteral Nutrition-Associated Liver Disease

Catherine Cibulskis, MD

Assistant Professor of Pediatrics

St. Louis University

The Haptoglobin 2-2 group randomised to Vitamin E

The Haptoglobin 2-2 group randomised to placebo

The Non Haptoglobin 2-2 group randomised to Vitamin E

The Non Haptoglobin 2-2 group randomised to placebo

Diabetes Mellitus

Two hundred patients will be recruited to a pilot randomized controlled trial (RCT), stratified by Hp 2-2 phenotype status (100 Hp 2-2 and 100 non-Hp 2-2), and randomly allocated in a 1:1 ratio to either vitamin E 400 IU supplementation daily for 6 months or a placebo group. The trial will determine whether vitamin E improves the aforementioned surrogate markers in the Hp phenotype strata.

Vitamin E

Placebo

Tan Tock Seng Hospital

Relationship of Haptoglobin Phenotype to Vascular Function and Response to Vitamin E Supplementation in Patients With Diabetes Mellitus Type 2: The EVAS Trial

Measured as Reactive hyperemia index using RHI-EndoPAT

Measured as pulse wave velocity using the sphygmocor device

Measured as ratio between retinal arterial diameter and venous diameter as retinal AV index

linolenic acid/asiņošana

Omegaven for Compassionate Use in the Treatment of Parenteral Nutrition-Associated Liver Disease

Relationship of Haptoglobin Phenotype to Vascular Function and Response to Vitamin E Supplementation in Patients With Diabetes Mellitus Type 2: The EVAS Trial

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne